---
title: "BridgeBio Pharma, Inc. (BBIO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BBIO.US.md"
symbol: "BBIO.US"
name: "BridgeBio Pharma, Inc."
industry: "Biotechnology"
datetime: "2026-04-15T23:45:33.612Z"
locales:
  - [en](https://longbridge.com/en/quote/BBIO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BBIO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BBIO.US.md)
---

# BridgeBio Pharma, Inc. (BBIO.US)

## Company Overview

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [bridgebio.com](https://bridgebio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:17.000Z

**Overall: C (0.44)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 81 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 126.26% |  |
| Net Profit YoY | -35.31% |  |
| P/B Ratio | -7.24 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 15107733537.03 |  |
| Revenue | 502076000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 40.79% | A |
| Profit Margin | -144.39% | E |
| Gross Margin | 95.82% | A |
| Revenue YoY | 126.26% | A |
| Net Profit YoY | -35.31% | D |
| Total Assets YoY | 1.82% | C |
| Net Assets YoY | -42.46% | E |
| Cash Flow Margin | 61.51% | C |
| OCF YoY | 126.26% | A |
| Turnover | 0.54 | C |
| Gearing Ratio | 321.85% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - BridgeBio Pharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "126.26%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-35.31%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-7.24",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "15107733537.03",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "502076000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "40.79%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-144.39%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "95.82%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "126.26%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-35.31%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.82%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-42.46%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "61.51%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "126.26%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.54",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "321.85%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -20.84 | 496/393 | - | - | - |
| PB | -7.24 | 525/393 | - | - | - |
| PS (TTM) | 30.09 | 224/393 | 53.17 | 41.60 | 34.21 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-12T04:00:00.000Z

Total Analysts: **23**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 16 | 70% |
| Overweight | 6 | 26% |
| Hold | 1 | 4% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 77.70 |
| Highest Target | 157.00 |
| Lowest Target | 80.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BBIO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BBIO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BBIO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BBIO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**